247 related articles for article (PubMed ID: 28888219)
21. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
Zhang F; Chen X; Wu T; Huang N; Li L; Yuan D; Xiang J; Wang N; Chen W; Zhang J
Clin Pharmacokinet; 2022 Jun; 61(6):881-893. PubMed ID: 35316848
[TBL] [Abstract][Full Text] [Related]
22. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Perzborn E; Heitmeier S; Buetehorn U; Laux V
J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
[TBL] [Abstract][Full Text] [Related]
23. Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS.
Liu H; Zhao Z; Wang Y; Liu L; Yang Y; An Z
Curr Drug Metab; 2021; 22(14):1132-1138. PubMed ID: 34825867
[TBL] [Abstract][Full Text] [Related]
24. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
Gosselin RC; Francart SJ; Hawes EM; Moll S; Dager WE; Adcock DM
Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
[TBL] [Abstract][Full Text] [Related]
25. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
26. Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).
Suzuki S; Morishima Y; Takita A; Otsuka T; Yagi N; Arita T; Yamashita T
Heart Vessels; 2020 Mar; 35(3):409-416. PubMed ID: 31522245
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
[TBL] [Abstract][Full Text] [Related]
28. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
Königsbrügge O; Weigel G; Quehenberger P; Pabinger I; Ay C
Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
[TBL] [Abstract][Full Text] [Related]
29. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
Derogis PB; Sanches LR; de Aranda VF; Colombini MP; Mangueira CL; Katz M; Faulhaber AC; Mendes CE; Ferreira CE; França CN; Guerra JC
PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
[TBL] [Abstract][Full Text] [Related]
30. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.
Nakano Y; Kondo T; Osanai H; Murase Y; Nakashima Y; Asano H; Ajioka M; Sakai K; Inden Y; Murohara T
J Cardiol; 2015 Mar; 65(3):185-90. PubMed ID: 25192594
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
32. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
[TBL] [Abstract][Full Text] [Related]
34. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
Ono R; Nishimura K; Takahashi H; Hori Y; Fukushima K; Kobayashi Y
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895
[TBL] [Abstract][Full Text] [Related]
35. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Steppich B; Dobler F; Brendel LC; Hessling G; Braun SL; Steinsiek AL; Deisenhofer I; Hyseni A; Roest M; Ott I
J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
[TBL] [Abstract][Full Text] [Related]
36. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
[TBL] [Abstract][Full Text] [Related]
37. Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1).
Suzuki S; Yamashita T; Kasai H; Otsuka T; Sagara K
Thromb Res; 2017 Feb; 150():73-75. PubMed ID: 28043042
[No Abstract] [Full Text] [Related]
38. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
39. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
Bolek T; Samoš M; Škorňová I; Stančiaková L; Staško J; Korpallová B; Galajda P; Kubisz P; Mokáň M
J Thromb Thrombolysis; 2019 Jan; 47(1):140-145. PubMed ID: 30288664
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
